LEGN / Legend Biotech set for clinical development of potential treatment for small cell lung cancer after FDA approval

Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykt more_horizontal

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Shares of Legend Biotech Corp. LEGN, -1.00% gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collabor more_horizontal

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multipl more_horizontal

If everyone expects a stock to rise and buys it, eventually someone will be wrong. Legend Biotech's shares are up by quite a bit this year already. more_horizontal

Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-b more_horizontal

Legend reportedly confirmed the leaked results of its multiple myeloma study on Friday, leading LEGN stock to surge. The post Legend Bio Hits Profit-T more_horizontal

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progressi more_horizontal